Karyopharm Therapeutics (KPTI) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Karyopharm Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $350K of KPTI stock on the open market.
Get emailed when insiders cluster-buy stocks like KPTI
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
KPTI insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $450 | 1 |
| Q3 2026 | — | 0 | $1K | 2 |
| Q2 2026 | — | 0 | $39K | 7 |
| Q1 2026 | — | 0 | $309K | 10 |
| Q4 2025 | — | 0 | $2K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Karyopharm Therapeutics Inc. insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $350K. 0 of 21 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Kristin AbateChief Accounting Officer | Sell | 37823,404 held (−2%) | $1.19 | $450 | -49.2% | — |
| Sep 2SEC | Kristin AbateChief Accounting Officer | Sell | 1923,782 held (−0%) | $2.02 | $38 | -70.0% | — |
| Jul 30SEC | Stuart PoultonEvp, Chief Development Officer | Sell | 18994,632 held (−0%) | $7.10 | $1K | -91.5% | — |
| May 15SEC | Richard A. PaulsonCEO, President | Sell | 2,203269,747 held (−1%) | $9.50 | $21K | -93.6% | — |
| May 15SEC | Reshma RangwalaEvp & Chief Medical Officer | Sell | 40856,829 held (−1%) | $9.50 | $4K | -93.6% | — |
| May 15SEC | Stuart PoultonEvp, Chief Development Officer | Sell | 40394,821 held (−0%) | $9.50 | $4K | -93.6% | — |
| May 15SEC | Sohanya Roshan ChengEvp & Chief Commercial Officer | Sell | 324107,940 held (−0%) | $9.50 | $3K | -93.6% | — |
| May 15SEC | Michael ManoGeneral Counsel | Sell | 26694,398 held (−0%) | $9.50 | $3K | -93.6% | — |
| May 15SEC | Kristin AbateChief Accounting Officer | Sell | 5323,801 held (−0%) | $9.50 | $504 | -93.6% | — |
| Apr 22SEC | Reshma RangwalaEvp & Chief Medical Officer | Sell | 44956,290 held (−1%) | $8.94 | $4K | -93.2% | — |
| Mar 3SEC | Richard A. PaulsonCEO, President | Sell | 12,361267,030 held (−4%) | $9.41 | $116K | -93.6% | — |
| Mar 3SEC | Stuart PoultonEvp, Chief Development Officer | Sell | 5,10194,328 held (−5%) | $9.41 | $48K | -93.6% | — |
| Mar 3SEC | Reshma RangwalaEvp & Chief Medical Officer | Sell | 5,06656,739 held (−8%) | $9.41 | $48K | -93.6% | — |
| Mar 3SEC | Sohanya Roshan ChengEvp & Chief Commercial Officer | Sell | 4,604107,317 held (−4%) | $9.41 | $43K | -93.6% | — |
| Mar 3SEC | Michael ManoGeneral Counsel | Sell | 3,52693,964 held (−4%) | $9.41 | $33K | -93.6% | — |
| Mar 3SEC | Kristin AbateChief Accounting Officer | Sell | 55922,063 held (−2%) | $9.41 | $5K | -93.6% | — |
| Feb 19SEC | Stuart PoultonEvp, Chief Development Officer | Sell | 37899,429 held (−0%) | $8.63 | $3K | -93.0% | — |
| Feb 4SEC | Lori MacomberCFO | Sell | 1,62685,105 held (−2%) | $6.30 | $10K | -90.4% | — |
| Jan 29SEC | Kristin AbateChief Accounting Officer | Sell | 5022,622 held (−0%) | $7.03 | $352 | -91.4% | — |
| Jan 22SEC | Kristin AbateChief Accounting Officer | Sell | 26522,580 held (−1%) | $5.96 | $2K | -89.8% | — |
| Oct 3SEC | Kristin AbateChief Accounting Officer | Sell | 36210,046 held (−3%) | $6.30 | $2K | -90.4% | — |
Insiders at Karyopharm Therapeutics Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Richard A. PaulsonCEO, President | — | $137K | May 15, 2026 | — |
| Stuart PoultonEvp, Chief Development Officer | — | $56K | Jul 30, 2026 | — |
| Reshma RangwalaEvp & Chief Medical Officer | — | $56K | May 15, 2026 | — |
| Sohanya Roshan ChengEvp & Chief Commercial Officer | — | $46K | May 15, 2026 | — |
| Michael ManoGeneral Counsel | — | $36K | May 15, 2026 | — |
| Kristin AbateChief Accounting Officer | — | $10K | Oct 2, 2026 | — |
| Lori MacomberCFO | — | $10K | Feb 4, 2026 | — |
KPTI stock: common questions
Are Karyopharm Therapeutics Inc. insiders buying KPTI stock?
In the past 12 months, 0 insiders reported open-market purchases of KPTI worth $0.
Are Karyopharm Therapeutics Inc. insiders selling KPTI stock?
7 insiders reported sales worth $350K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is KPTI's 52-week range?
Over the past year KPTI has traded between $0.60 and $10.67. It last closed at $0.60 on Oct 9, 2026.